MSACL 2017 EU Abstract

Prospects of Apolipoprotein Profiling for Precision Cardiovascular Diagnostics

Christa Cobbaert (Presenter)
Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, Leiden, the Netherlands

Short Abstract

Lipid abnormalities account for more than 60% of the population attributable risk for myocardial infarction and are the most important single target for prevention, together with smoking cessation and blood pressure lowering. Although statin therapy is the cornerstone of dyslipidemia management, LDLc lowering with statins reduces major coronary events by only one quarter, with 75% of events still occurring. Dyslipidemic patients remain at high Residual vascular Risk despite treatment for high LDLc in accordance with current standards of care. Atherogenic dyslipidemia is a key factor associated with Residual vascular Risk. So far, atherogenic dyslipidemia is largely under-diagnosed and under-treated in clinical practice as only overall lipid classes are measured rather than detailed molecular entities with specific functionalities. Comprehensive protein biomarkers are needed to obtain a better understanding of incident cardiovascular disease, but also for improved patient selection for evaluating treatment efficacy and safety. Recent mass spectrometry advances enable deep apolipoprotein proteomics to uncover mechanisms of coronary disease risk.

Long Abstract

References & Acknowledgements:

Financial Disclosure

Board Memberno

IP Royalty: no

Planning to mention or discuss specific products or technology of the company(ies) listed above: